PUBLISHER: DataM Intelligence | PRODUCT CODE: 1179911
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1179911
The global metered dose inhaler market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
A metered-dose inhaler (MDI) is a pressurized inhaler that delivers medication using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.
The market for metered dose inhalers is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.
The rising adoption of breathing-actuated inhalers and increasing investment in research and development are expected to drive the market's growth.
The metered dose inhaler market is driven by rising advancements in technology, an increase in demand for metered dose inhalers, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.
Technological advances have resulted in increasing metered dose inhaler adoption. The rising number of respiratory disorders, and increasing awareness among people about advanced respiratory devices like bronchodilators inhalers and bronchodilators inhalers for respiratory disorders, which have beneficial features over the traditional treatment methods and rising healthcare expenditure by governments and the private sector, could lead to higher infrastructure investments and drive the metered dose inhaler market.
Various novel product launches and research studies contribute to the market's growth. For instance, in May 17, 2022, Teva Pharmaceuticals, a Teva Pharmaceutical Industries Ltd. affiliate, announced its novel study findings based on the usage of short-acting beta agonist (SABA)'s novel established clinical thresholds that highlight real-world use of SABA in asthma patients in the U.S. and the potential for a digital inhaler, ProAir Digihaler (albuterol sulfate) inhalation powder.
The environmental or side effects associated with metered-dose inhalers are expected to hamper the market's growth.
However, metered dose inhalers release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA) biohazard nature propellants, which negatively impact the metered dose inhalers market's growth.
Stringent rules and regulations for approval of these metered dose inhalers and adverse events such as trembling, palpitations, nervous tension, muscle cramps, and others linked with bronchodilators hinder the market growth.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The metered dose inhaler market has experienced huge losses due to COVID as various research, and clinical trials got postponed due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.
The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The bronchodilators segment is the highest market holder in the global metered dose inhaler market. The global metered dose inhaler market is segmented based on medications in corticosteroids, bronchodilators, and combinations (corticosteroids & bronchodilators). The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.
These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), who experienced asthma exacerbations.
North America holds the largest market share in the global metered dose inhaler market.
North America dominates the global metered dose inhaler market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults in the United States suffered from chronic obstructive pulmonary disease (COPD) in 2020. And 25 million had asthma.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of medications of metered dose inhalers in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the metered dose inhaler market.
Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in September 21, 2020, Teva Respiratory, LLC., Teva Pharmaceutical Industries Ltd. affiliate announced the launch of two digital maintenance inhalers AirDuo Digihaler (salmeterol and fluticasone propionate) and ArmonAir Digihaler (fluticasone propionate) inhalation powder, for patients with asthma. AirDuo Digihaler is a prescription medicine used to prevent wheezing and control asthma symptoms in people 12 years and older.
The metered dose inhaler market is highly competitive with local and global companies' presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in April 9, 2020, Cipla Limited announced receiving final approval from the United States Food and Drug Administration (US FDA) for its inhalation aerosol, Albuterol Sulfate 90mcg (base)/actuation's abbreviated new drug application (ANDA). This is Cipla's first AB-rated generic therapeutic similar version of Proventil HFA Inhalation Aerosol of Merck Sharp & Dohme Corp's. It is utilized for treating acute episodes of bronchospasm or asthmatic symptoms prevention.
Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.
Proventil HFA: Proventil HFA (albuterol sulfate) inhalation aerosol is used for reversible obstructive airway disease, like asthma, and to treat or prevent bronchospasm in four years and older patients.
Key Development: In March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. With this acquisition, Sandoz acquired Coalesce's significant capabilities that can help build on its existing respiratory medicines portfolio.
The global metered dose inhaler market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.
LIST NOT EXHAUSTIVE